Dragos Damian (photo) will return to his former position as chief executive of Cluj-based drug maker Terapia, company acquired in 2006 by the Indian-based giant Ranbaxy Laboratories. Damian stepped down from his post in mid October as chief executive of Actavis, after only three months at the Icelandic-based company.
Apart from running the shortest mandate in the Romanian drug manufacturing, the growth of its peer, Zentiva resulting from Sanofi-Aventis deal, has been the underlying reason of Terapia Ranbaxy’s move. The aggregation of the two companies’ businesses pushes Sanofi-Aventis to the leading position of the local drug market.
Zentiva and Ranbaxy have entered a head-to-head competition for the leading position in the local market. Once the integration in Sanofi-Aventis, Zentiva leaves his peer far behind. The experience of Dragos Damian at the helm of Ranbaxy, together with his year-and a half-long term at Zentiva could help the Cluj-based producer recover the lost ground.
In lipsa unui acord scris din partea InternetCorp, puteti prelua maxim 500 de caractere din acest articol daca precizati sursa si daca inserati vizibil linkul articolului Dragos Damian retakes CEO position at Terapia.